#1 Clinical Trials Search in Europe

Dermatophagoides Farinae

This article discusses recent clinical trials investigating the use of Dermatophagoides Farinae (house dust mite) extract in treating allergic asthma and rhinitis. These studies aim to evaluate the safety and effectiveness of various treatments, including allergen immunotherapy and novel anti-inflammatory drugs, in managing allergic reactions to house dust mites. The trials focus on different aspects of allergic responses, such as airway inflammation, lung function, and immune system activity.

Table of Contents

What is Dermatophagoides Farinae?

Dermatophagoides Farinae, also known as house dust mite allergen extract, is a substance used in the treatment of allergies[1]. It is derived from a specific species of dust mite, which is a common cause of allergies in many people. This extract is used both as a diagnostic tool and as a treatment for allergic conditions, particularly those related to dust mite allergies[3].

Conditions Treated

Dermatophagoides Farinae is primarily used to treat the following conditions:

  • Allergic Asthma: A type of asthma triggered by allergens, in this case, dust mites[1].
  • Allergic Rhinitis: Also known as hay fever, this condition causes symptoms like sneezing, runny nose, and itchy eyes when exposed to allergens[3].
  • House Dust Mite Rhinitis: A specific form of allergic rhinitis caused by dust mites[3].

How It Works

Dermatophagoides Farinae works through a process called immunotherapy. Here’s a simplified explanation of how it functions:

  1. Exposure: The patient is exposed to small, controlled amounts of the allergen (dust mite extract).
  2. Immune Response: This exposure triggers the immune system to respond.
  3. Desensitization: Over time, the immune system becomes less sensitive to the allergen.
  4. Tolerance: Eventually, the body develops a tolerance, reducing allergic reactions when exposed to dust mites in everyday life[1][2].

Administration and Dosage

Dermatophagoides Farinae is typically administered in the following ways:

  • Inhalation: In some clinical trials, it is given as an inhaled allergen challenge[1].
  • Subcutaneous Injection: It can be injected under the skin in gradually increasing doses[3].

The dosage varies depending on the specific treatment protocol. For example, in one study, the extract was standardized at 30,000 allergen units (AU)/mL[1]. In another study, doses ranged from 100 PAU (Protein Allergen Units) to 800 PAU, with a gradual increase over several weeks[3].

Clinical Trials and Research

Several clinical trials are investigating the effectiveness of Dermatophagoides Farinae in treating allergic conditions:

  • A study examining its use as a rescue treatment for allergic airway inflammation[1].
  • Research on its effectiveness when administered during different phases of an allergic response[2].
  • A trial comparing different doses to evaluate safety and immune-stimulating efficacy[3].

Potential Side Effects

As with any medical treatment, Dermatophagoides Farinae may cause side effects. Researchers carefully monitor for:

  • Local reactions: Such as redness or swelling at the injection site[3].
  • Systemic reactions: These are whole-body responses, which can range from mild to severe[3].
  • Changes in lung function: Measured by tests like FEV1 (Forced Expiratory Volume in 1 second)[1].
  • Changes in airway inflammation: Monitored through various tests including sputum analysis and exhaled nitric oxide levels[1][2].

Important Considerations

When considering treatment with Dermatophagoides Farinae, keep in mind:

  • It’s typically used for people with confirmed dust mite allergies.
  • Treatment is usually long-term, often lasting several months to years.
  • Regular follow-ups with your allergist are crucial to monitor progress and adjust treatment as needed.
  • This treatment aims to reduce symptoms and improve quality of life, but it may not completely cure the allergy.

Always consult with a healthcare professional before starting any new treatment, as they can provide personalized advice based on your specific health situation.

Aspect Details
Main Focus Evaluation of treatments for allergic asthma and rhinitis caused by Dermatophagoides Farinae (house dust mite)
Key Treatments Anakinra (IL-1 blocker), Allergen immunotherapy using Dermatophagoides Farinae extract
Primary Outcomes Changes in lung function (FEV1), airway inflammation, safety and tolerability of treatments
Secondary Outcomes Mucociliary clearance, sputum composition, airway hyper-responsiveness, biomarkers of inflammation
Study Designs Randomized, double-blind, placebo-controlled trials with crossover or parallel group designs
Patient Population Adults with mild allergic asthma or allergic rhinitis sensitized to Dermatophagoides Farinae
Safety Assessments Vital signs, physical examinations, blood tests, electrocardiograms, adverse event monitoring

FAQ

  • What is Dermatophagoides Farinae? Dermatophagoides Farinae is a species of house dust mite. In these clinical trials, it is used as an allergen extract to provoke allergic responses in patients with asthma or allergic rhinitis who are sensitized to this particular mite species.
  • What are the main objectives of these clinical trials? The main objectives include evaluating the safety and effectiveness of different treatments for allergic asthma and rhinitis caused by house dust mites. Some trials focus on testing new drugs like Anakinra, while others examine immunotherapy approaches using Dermatophagoides Farinae extract.
  • How is lung function measured in these trials? Lung function is primarily measured using Forced Expiratory Volume in 1 second (FEV1). This test measures how much air a person can exhale in one second, which helps assess the severity of airway obstruction and the effectiveness of treatments.
  • What is a late phase response (LPR) in allergic reactions? The late phase response (LPR) occurs 3-7 hours after initial allergen exposure. It involves the release of inflammatory chemicals that cause airway constriction, increased mucus production, and airway hyper-reactivity. The LPR is a key focus in some of these trials.
  • How is the safety of treatments evaluated in these trials? Safety is evaluated through various methods, including monitoring vital signs (blood pressure, heart rate, body temperature), physical examinations, blood tests, electrocardiograms, and assessment of local and systemic adverse events. Researchers closely observe participants for any negative reactions throughout the trials.

Ongoing Clinical Trials on Dermatophagoides Farinae

  • Study of sublingual immunotherapy with Dermatophagoides pteronyssinus and Dermatophagoides farinae allergen mix for patients with dust mite allergic rhinitis

    Recruiting

    1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on the Effectiveness of Dermatophagoides Allergen Extracts and Histamine Dihydrochloride for Patients with Allergies

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on Allergenic Extracts of Mites and Histamine Dihydrochloride for Allergy Patients

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on the Effectiveness of PURETHAL Mites for Adults with Moderate to Severe Allergic Rhinitis or Rhinoconjunctivitis Due to House Dust Mite Allergy

    Not recruiting

    1 1 1
    Investigated drugs:
    Austria Bulgaria Germany Latvia Lithuania Poland

Glossary

  • Allergen: A substance that can cause an allergic reaction in some people. In these trials, the main allergen is Dermatophagoides Farinae, a type of house dust mite.
  • FEV1: Forced Expiratory Volume in 1 second, a measure of how much air a person can exhale in one second. It's used to assess lung function and airway obstruction.
  • Anakinra: A medication that blocks the activity of interleukin-1 (IL-1), an inflammatory molecule. It's being tested as a potential treatment for allergic airway inflammation.
  • Immunotherapy: A treatment approach that aims to modify the immune system's response to allergens, potentially reducing allergic symptoms over time.
  • Airway hyper-reactivity (AHR): An exaggerated narrowing of the airways in response to various stimuli, which is a characteristic feature of asthma.
  • Mucociliary clearance (MCC): The process by which the airways clear mucus and trapped particles. It's an important defense mechanism in the respiratory system.
  • Sputum: A mixture of saliva and mucus coughed up from the respiratory tract, often examined in these trials to assess airway inflammation.
  • Eosinophils: A type of white blood cell involved in allergic reactions and asthma. Their levels in sputum are often measured to assess allergic inflammation.
  • Neutrophils: Another type of white blood cell that plays a role in inflammation. Their levels in sputum are also measured in some of these trials.
  • Fractional exhaled Nitric Oxide (FeNO): A biomarker of airway inflammation, measured in exhaled breath. It's used as a non-invasive way to assess allergic airway inflammation.

References

  1. https://clinicaltrials.gov/study/NCT03513471
  2. https://clinicaltrials.gov/study/NCT03513458
  3. https://clinicaltrials.gov/study/NCT05525650